Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT04899479

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04899479
Other papers using this trial's data
  • SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI JACC. Cardiovascular interventions, 2026-07-27 DOI, PubMed 42508844

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04899479. Randomized; no masking; primary purpose treatment. Start 2021-07-05 (actual); primary completion 2025-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
Acronym
PRESTIGE-AMI
Condition
Acute Myocardial Infarction
Condition
Heart Failure
Intervention (Drug)
SGLT2 inhibitor
Intervention (Other)
Control
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct04899479
Content hash
c9ca293fd41c889138941c38ab09f5a2c4bdb038c897a8da06e733151ace675f